Evidence map›Paper›PMID 32504188›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2020

Cytotoxic T lymphocyte antigen-4 (CTLA-4) expression in chordoma and tumor-infiltrating lymphocytes (TILs) predicts prognosis of spinal chordoma.

G He, X Liu, X Pan, Y Ma, X Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

G HeDepartment of Orthopedics, North Garden Street, Peking University Third Hospital, No. 49, Haidian District, Beijing, 100191, People's Republic of China.ORCID http://orcid.org/0000-0001-9088-5110
X LiuDepartment of Orthopedics, North Garden Street, Peking University Third Hospital, No. 49, Haidian District, Beijing, 100191, People's Republic of China.
X PanDepartment of Orthopedics, North Garden Street, Peking University Third Hospital, No. 49, Haidian District, Beijing, 100191, People's Republic of China.
Y MaThe Center for Pain Medicine, North Garden Street, Peking University Third Hospital, No. 49, Haidian District, Beijing, 100191, China.
X LiuDepartment of Orthopedics, North Garden Street, Peking University Third Hospital, No. 49, Haidian District, Beijing, 100191, People's Republic of China. xglius@vip.sina.com.
Peking University · CN

Funding

Beijing Natural Science Foundation 7192226National Natural Science Foundation 81802686
6 · The paper itself

Abstract

purposeChordoma is a rare tumor of the skeletal system that is characterized by a high recurrence rate and treatment resistance. Given the common finding of immune dysregulation in chordoma, immunotherapy has emerged as potential treatment option. As an important immune checkpoint regulator, we evaluated cytotoxic T-lymphocyte antigen-4 (CTLA-4) expression and its prognostic significance for patients with chordoma of the spine.

methodsCTLA-4 expression was analyzed immunohistochemically in 32 chordoma tissues and 14 nucleus pulposus tissues to examine the specificity of CTLA-4 expression in chordoma. Univariate log-rank analysis was used to evaluate the association of CTLA-4 expression in tumor cells and tumor-infiltrating lymphocytes (TILs) with survival. Cox multivariate analysis was used to identify independent factors of survival.

resultsPositive CTLA-4 expression was observed in all of the TILs and tumor cell cytoplasm, and partial in the membrane or in both the membrane and nucleus, with a markedly higher positivity rate than that observed in normal nucleus tissues. Higher CTLA-4 expression in the tumor but not in TILs was significantly associated with shorter continuous disease-free survival (CDFS) and overall survival (OS). CTLA-4 expression in tumor cells and TILs were independent predictors for CDFS, whereas only tumor cell expression was a significant predictor of OS. Furthermore, the combination of CTLA-4 expression in the tumor and TILs had higher prognostic value.

conclusionsTargeting CTLA-4 may be a potential novel therapeutic strategy for chordoma patients.

Indexed as

AdolescentAdultAgedChildChordomaCTLA-4 AntigenDisease-Free SurvivalFemaleHumansImmunotherapyLymphocytes, Tumor-InfiltratingMaleMiddle AgedNucleus PulposusPrognosisProportional Hazards ModelsCTLA-4 AntigenCTLA4 protein, humanChordomaCTLA-4ImmunohistochemistryPrognosisTILs

Identifiers

PMID32504188
OpenAlexW3033781001

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.